

# Reena S Cecchini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6738471/publications.pdf>

Version: 2024-02-01

31  
papers

5,020  
citations

331670

21  
h-index

454955

30  
g-index

32  
all docs

32  
docs citations

32  
times ranked

5076  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P1-07-04: Potential role of the antibody-dependent cellular phagocytosis (ADCP) in tumors achieving pCR in NRG Oncology/NSABP B-52. <i>Cancer Research</i> , 2022, 82, P1-07-04-P1-07-04.	0.9	0
2	Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1105-1108.	6.3	5
3	NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab. <i>Npj Breast Cancer</i> , 2021, 7, 55.	5.2	4
4	Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. <i>Journal of Clinical Oncology</i> , 2021, 39, 3800-3812.	1.6	6
5	A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 161-171.	2.5	39
6	NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. <i>Journal of Clinical Oncology</i> , 2020, 38, 444-453.	1.6	234
7	Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. <i>Lancet, The</i> , 2019, 394, 2155-2164.	13.7	319
8	Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey. <i>Contemporary Clinical Trials Communications</i> , 2018, 10, 100-104.	1.1	8
9	Meta-analysis of the cardiac events in the adjuvant trastuzumab trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10066-10066.	1.6	2
10	Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. <i>Journal of Clinical Oncology</i> , 2017, 35, 3942-3948.	1.6	55
11	Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. <i>Lancet, The</i> , 2016, 387, 849-856.	13.7	148
12	Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. <i>Lancet, The</i> , 2016, 387, 857-865.	13.7	67
13	Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 51-59.	2.5	33
14	Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1500-1500.	1.6	5
15	Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA500-LBA500.	1.6	12
16	Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA500-LBA500.	1.6	0
17	Baseline Mammographic Breast Density and the Risk of Invasive Breast Cancer in Postmenopausal Women Participating in the NSABP Study of Tamoxifen and Raloxifene (STAR). <i>Cancer Prevention Research</i> , 2012, 5, 1321-1329.	1.5	23
18	Body Mass Index and the Risk for Developing Invasive Breast Cancer among High-Risk Women in NSABP P-1 and STAR Breast Cancer Prevention Trials. <i>Cancer Prevention Research</i> , 2012, 5, 583-592.	1.5	93

#	ARTICLE	IF	CITATIONS
19	Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. <i>Cancer</i> , 2012, 118, 5614-5622.	4.1	76
20	25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1077-1088.	2.5	51
21	Adolescents' Experiences Using the Contraceptive Patch versus Pills. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2011, 24, 197-203.	0.7	19
22	Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 535.e1-535.e5.	1.3	48
23	Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 1110-1116.	1.6	108
24	Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. <i>Cancer Prevention Research</i> , 2010, 3, 696-706.	1.5	560
25	Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 315-320.	2.5	93
26	The Use of Tamoxifen and Raloxifene for the Prevention of Breast Cancer. <i>Recent Results in Cancer Research</i> , 2009, 181, 113-119.	1.8	29
27	Quality of Life in Operable Colon Cancer Patients Receiving Oral Compared With Intravenous Chemotherapy: Results From National Surgical Adjuvant Breast and Bowel Project Trial C-06. <i>Journal of Clinical Oncology</i> , 2007, 25, 424-430.	1.6	60
28	Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07. <i>Journal of Clinical Oncology</i> , 2007, 25, 2205-2211.	1.6	206
29	An Association Between Postoperative Radiotherapy for Primary Breast Cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) Studies and the Subsequent Appearance of Pleural Mesothelioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 294-296.	1.3	25
30	Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<sub>TITLE</sub>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial<sub>TITLE</sub>. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2727.	7.4	1,499
31	Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1652-1662.	6.3	1,192